Related by context. All words. (Click for frequent words.) 69 O PPDS 67 tapentadol ER 66 APTIVUS r 66 dose proportional pharmacokinetics 66 VAPRISOL 66 serum cortisol 65 analgesic efficacy 65 pharmacodynamic PD 65 latanoprost 65 inhaled iloprost 65 bronchodilation 65 symptomatic paroxysmal AF 65 isoproterenol 65 hyperalgesia 65 CIMZIA TM 65 fosbretabulin 64 AST ALT 64 desvenlafaxine succinate 64 Traficet EN 64 tacrolimus ointment 64 Toxicities 64 intravitreal injections 64 dose proportionality 64 CIMZIA ™ 64 IOP lowering 64 serum urate 64 zonisamide SR 64 dosage regimens 64 viral kinetics 64 timolol 64 QTc prolongation 64 nadolol 64 octreotide LAR 64 Protelos 64 dose Iluvien 64 transaminase elevations 63 rFVIIa 63 teriflunomide 63 paroxysmal AF 63 IFN α 63 macroalbuminuria 63 bolus dose 63 systemic hypotension 63 noninfectious uveitis 63 riociguat 63 CANCIDAS 63 plasma pharmacokinetics 63 somatostatin analog 63 ximelagatran 63 pimecrolimus 63 tipranavir r 63 nonrandomized 63 coadministration 63 TMC# r 63 liposome formulation 63 lacosamide 63 ULORIC 63 cinacalcet 63 salmeterol fluticasone 63 platelet inhibitor 63 subcutaneously administered 63 neutropaenia 63 divalproex sodium 63 velafermin 63 fluticasone salmeterol 63 imatinib therapy 63 clinically meaningful reductions 62 pharmacokinetic characteristics 62 EVIZON 62 antiangiogenic therapy 62 KAPIDEX 62 pimecrolimus cream 62 mg kg BID 62 CONCERTA 62 morphometric vertebral fractures 62 ziconotide 62 neovascular 62 cerebral vasospasm 62 ATACAND 62 vidofludimus 62 serum HBV DNA 62 Acute Ischemic Stroke 62 synthetic retinoid 62 PROMACTA 62 systemic bioavailability 62 octreotide 62 clevidipine 62 Non inferiority 62 perfusion abnormalities 62 olopatadine 62 CIMZIA TM certolizumab pegol 62 nephrotoxicity 62 atrioventricular block 62 liposomal amphotericin B 62 levetiracetam 62 moderate plaque psoriasis 62 mitomycin C 62 Tolvaptan 62 Hypotension 62 Vaprisol 62 thrombolytic agents 62 favorable pharmacokinetic profile 62 Patency 62 leukocyte count 62 efficacy tolerability 62 ritonavir boosted 62 Serum creatinine 62 rHuPH# 62 pyridostigmine 62 antiarrhythmic drug 62 Bezielle 62 ALA PDT 62 refractory AML 62 H2RAs 62 pharmacokinetic PK profile 62 intravenous dosing 62 aminotransferases 61 hypercalcemia 61 ARIKACE 61 dermatologic toxicities 61 FDG PET imaging 61 INVEGA ® 61 ocular hypertension 61 pharmacodynamics PD 61 eculizumab therapy 61 symptomatic intracranial hemorrhage 61 chloride secretion 61 myocardial reperfusion 61 nicardipine 61 Pharmacokinetic parameters 61 Glypromate 61 oral levofloxacin 61 metered dose inhaler MDI 61 somatostatin analogues 61 Lacosamide 61 NATRECOR ® 61 PegIFN RBV 61 amphotericin B 61 fallopian tube cancers 61 IL 1ß 61 hemorrhagic complications 61 PREZISTA r 61 myopathy rhabdomyolysis 61 Teriflunomide 61 dorzolamide 61 CIPN 61 #beta estradiol 61 certolizumab 61 coronary stenosis 61 DACH platinum 61 Pegasys ® 61 intravitreal injection 61 APTIVUS 61 pharmacokinetic PK 61 MoxDuo 61 demonstrated clinically meaningful 61 CIMZIA R 61 thromboembolic events 61 fluticasone furoate 61 paroxysmal atrial fibrillation 61 BROVANA 61 intermittent dosing 61 MACUGEN 61 biologic DMARD 61 pharmacodynamic parameters 61 resynchronization therapy 61 dopamine partial agonist 61 myeloproliferative diseases 61 timepoints 61 liposome injection 61 PREZISTA ritonavir 61 ara C 61 corticosteroid therapy 61 hematologic toxicity 61 metastatic neuroendocrine tumors 61 delayed CINV 61 recurrent glioma 61 docetaxel Taxotere ® 61 KETEK 61 conjunctival hyperemia 61 DLTs 61 TNF alpha inhibitor 61 FFNS 61 Zemplar Capsules 61 intravesical 61 antithrombotics 61 denileukin diftitox 61 systemic absorption 61 BARACLUDE r 61 macrolide antibiotic 61 ACTEMRA TM 61 relapsed MM 61 pharmacokinetic interactions 61 trospium 61 Azedra 61 subcutaneous infusion 61 colesevelam HCl 61 double blinded placebo 61 CorVue ™ 61 symptomatic VTE 61 icatibant 61 QTc intervals 61 GI motility 61 ropivacaine 61 Primary endpoints 61 photocoagulation 61 mg kg dose 61 MAGE A3 ASCI 61 serum phosphorous 61 cobiprostone 61 intratumoral 61 SCIg 61 hemodilution 61 anterior uveitis 61 oral rivaroxaban 61 biodistribution 61 topical diclofenac 61 BENICAR HCT 61 LHRH antagonists 61 mcg BID 61 steroid dexamethasone 61 active comparator 61 cannabinor 61 uric acid lowering 61 cardiac perfusion 60 mg/m2 dose 60 angiographic outcomes 60 ALGRX 60 dosing frequency 60 proton pump inhibitor PPI 60 Degarelix 60 tolterodine 60 somatostatin analogue 60 glatiramer acetate 60 RSD# oral 60 evaluable subjects 60 Ophena TM 60 ISTODAX 60 postoperative morbidity 60 INC# 60 CRVO 60 ALT elevations 60 CTEPH 60 Retisert 60 tolerability profiles 60 SPRIX ® 60 NovoSeven ® 60 HBeAg seroconversion 60 inflammatory acne 60 timolol maleate 60 piperacillin tazobactam 60 caspofungin 60 XIENCE V PROMUS Stent 60 IFN beta 60 sitaxsentan 60 DAPT 60 ketorolac 60 nimodipine 60 MoxDuo TM IR 60 cerebral ischemia 60 ARCOXIA 60 azacitidine 60 brivaracetam 60 bromfenac 60 paricalcitol 60 HuMax EGFr 60 iPTH 60 Nebulized 60 ALVESCO 60 pharmacokinetics PK 60 Aliskiren 60 hepatocellular 60 fluocinolone acetonide 60 milrinone 60 topical formulation 60 GAMMAGARD 60 interferon γ 60 oral anticoagulation 60 chlorambucil 60 urate lowering 60 chemoradiotherapy 60 rhEPO 60 retinal vein occlusion 60 nab paclitaxel 60 radiotherapy RT 60 Fulvestrant 60 colorectal adenoma 60 pain palliation 60 primidone 60 bronchial hyperresponsiveness 60 adalimumab 60 EXJADE 60 BrachySil TM 60 decitabine 60 Febrile neutropenia 60 locoregional disease 60 TPV r 60 EGFR HER2 60 XIENCE V stent 60 4mg/kg 60 AGILECT R 60 left ventricular diastolic 60 chemoradiation therapy 60 postsurgical pain 60 juvenile idiopathic arthritis 60 remifentanil 60 ecabet sodium 60 aldosterone antagonist 60 glomerular filtration 60 Butrans 60 trabeculectomy 60 myocardial necrosis 60 F FDG PET 60 moderate renal impairment 60 multicenter randomized placebo controlled 60 NP2 Enkephalin 60 paraprotein 60 CsA 60 dimeglumine 60 ibandronate 60 pharmacokinetic profiles 60 TAXUS Liberte Stent 60 oral prodrug 60 RAPAFLO R 60 rosuvastatin #mg 60 OMS# 60 trials RCTs 60 effector function 60 busulfan 60 Candesartan 60 CHOP chemotherapy 60 eplerenone 60 haematologic 60 tegaserod 60 Dasatinib 60 intravitreal insert 60 colorectal liver metastases 60 FOSRENOL ® 60 natriuresis 60 p = NS 60 intravascular hemolysis 60 serum phosphate 60 ciclesonide 60 Pharmacokinetics PK 60 insulin detemir 60 Tiotropium 60 intravenous IV infusion 60 calcineurin inhibitor 60 Cimzia TM 60 CA4P 60 hemostatic efficacy 60 ARCALYST ® 60 CCX# 60 rt PA 60 Durezol 60 QTc 60 central corneal thickness 60 Dabigatran etexilate 60 pegaptanib 60 transurethral 60 peginterferon alfa 2a 60 Aclidinium 59 calcineurin inhibitors 59 hypomagnesemia 59 subcutaneous SC 59 Sumatriptan OS 59 OAB symptoms 59 drotrecogin alfa activated 59 detrusor 59 DDP# 59 vapreotide acetate 59 systemic corticosteroid 59 dosage regimen 59 elevated IOP 59 elevated creatinine 59 LPS induced 59 ascending dose 59 mg BID dose 59 ESBA# 59 hyperphenylalaninemia HPA due 59 PASI scores 59 gastroduodenal 59 ocular allergies 59 Pemetrexed 59 C1 INH 59 intracranial hemorrhage ICH 59 Neulasta ® 59 afterload 59 conventional DMARDs 59 oral diclofenac 59 ALB # 59 INCB# [003] 59 maximally tolerated dose 59 baroreflex 59 eszopiclone 59 beta blocker therapy 59 docetaxel chemotherapy 59 lavage 59 mecamylamine 59 sotalol 59 TMS Therapy 59 ZYVOX 59 thrombotic complications 59 NPH insulin 59 vertebral compression fractures 59 Raptiva r 59 ocular inflammation 59 doxorubicin docetaxel 59 tolvaptan 59 chronic LBP 59 idarubicin 59 herpetic keratitis 59 granisetron 59 plasma kallikrein inhibitor 59 rebleeding 59 bronchodilatory 59 PEG IFN 59 LODOTRA 59 coagulopathy 59 QD dosing 59 rituximab Rituxan 59 tissue oxygenation 59 IV bisphosphonates 59 endophthalmitis 59 antiepileptics 59 mixed hyperlipidemia 59 SERCA2a 59 SCH # 59 SSRI citalopram 59 idraparinux 59 epoetin alpha 59 micafungin 59 corticosteroid dose 59 intravitreal bevacizumab 59 SpO 2 59 RAPAFLO 59 urinary N telopeptide 59 5FU 59 β blockers 59 SPIRIVA R 59 aspartate aminotransferase 59 visilizumab 59 diabetic neuropathic pain 59 immunosuppressives 59 metastatic RCC 59 FXIII 59 Navelbine 59 abacavir lamivudine 59 thorough QT 59 antiviral efficacy 59 liposomal formulation 59 blood Phe 59 Rilonacept 59 epoprostenol 59 multidose 59 GORE TAG Device 59 Interferon beta 1a 59 budesonide formoterol 59 posaconazole 59 solithromycin 59 intravenous diuretics 59 certolizumab pegol 59 OMNARIS HFA 59 NATRECOR R 59 immunomodulatory therapy 59 guanfacine 59 evaluating tivozanib 59 STRIDE PD 59 Certolizumab pegol 59 Arikace 59 TG# [003] 59 rilonacept 59 clobazam 59 SVR# 59 mcg mL 59 adrenal suppression 59 LAB CGRP 59 Bronchial Thermoplasty 59 GHRH 59 antiangiogenic agents 59 moderate hepatic impairment 59 percutaneous tibial nerve 59 MoxDuo IR 59 virologic response 59 oral prednisolone 59 Betaferon ® 59 hemoglobin Hb 59 PSA nadir 59 SGPT 59 transcranial Doppler ultrasound 59 venous thromboembolic disease 59 ruboxistaurin 59 Known hypersensitivity 59 overactive bladder syndrome 59 bi ventricular pacing 59 EFFEXOR XR 59 ADAGIO study 59 Sym# 59 PAOD 59 deferiprone 59 Pegylated Liposomal Doxorubicin 59 Xanafide 59 TORISEL 59 solifenacin 59 postoperative hemorrhage 59 vitreous hemorrhage 59 Interferon alfa 59 percutaneous vertebroplasty 59 dyssynchrony 59 carotid artery stenosis 59 HIF PHI 59 CPAP adherence 59 ancrod 59 oxcarbazepine 59 Q#IR 59 edifoligide 59 inecalcitol 59 serum phosphorus 59 8mg/kg 59 CP CPPS 59 prospective multicenter randomized 59 urography 59 phototoxicity 59 MGd 59 vasogenic edema 59 choroidal neovascularization 59 cefotaxime 59 histrelin 59 inhaled nitric oxide 59 linear pharmacokinetics 59 oxybutynin 59 treprostinil 59 mu opioid receptor antagonist 59 orally inhaled 59 LIPUS 59 LB# [003] 59 pharmacodynamic effects 59 Dapagliflozin 59 interferon ribavirin 59 GSK# [001] 59 DOXIL 59 sub maximal 59 contrast induced nephropathy 59 mcg QD 59 zotarolimus 59 RX ACCULINK 59 mitomycin 59 apremilast 59 lomitapide 59 serum bilirubin 59 Interferon beta 59 myocardial revascularization 59 neuroleptic 59 dose limiting toxicities 59 dose titration 59 beta lactamase inhibitor 59 selective modulator 59 erythropoietic 59 bosentan 59 allodynia 59 FOLPI 59 radicular pain 59 intra ocular pressure 59 cilengitide 59 sirolimus eluting stent 59 tumor xenograft models 59 ROCKET AF 59 prucalopride 59 xanthine oxidase inhibitor 59 voriconazole 59 Ceplene/IL-2 59 ARB telmisartan 59 TNFalpha 59 severe hypersensitivity reactions 59 Orthokine 59 functional mitral regurgitation 59 TREDAPTIVE 59 Peg IFN 59 platelet inhibition 59 GAMMAGARD LIQUID 59 inotropic 59 gadobutrol 59 pharmacokinetic profile 59 RE LY ® 59 symptomatic intracranial 59 intraventricular 59 FLECTOR R Patch 59 achieved statistical significance 59 Keppra R 59 Capesaris 59 diarrhea predominant irritable 59 HIF PH inhibitors 59 TURBT 59 CLORETAZINE TM VNP#M 59 administered subcutaneously 59 choroidal neovascularization CNV 59 unfractionated heparin UFH 59 ß blockers 59 Gabapentin GR 59 pegylated IFN 59 EOquin 59 EQUETRO 59 MicroPulse 59 valvulopathy 59 clonidine hydrochloride 58 BANZEL 58 oxycodone CR 58 PRISTIQ 58 demonstrated antitumor activity 58 μg liter 58 nCPAP 58 immunosuppressive therapies 58 Cypher Stent 58 sustained virological response 58 BAL# [002] 58 acute GvHD 58 Neovascular AMD 58 hematological toxicity 58 retinal thickness 58 plus ribavirin 58 prokinetic agent 58 Retisert TM 58 PROMUS Element Stent 58 mometasone furoate 58 intraocular pressure IOP 58 lumbar spinal stenosis LSS 58 CR nPR 58 GOUT 58 DuraSite 58 microbiological eradication 58 intravenous cyclophosphamide 58 imiquimod cream 58 DUROS 58 SHPT 58 HPA axis suppression 58 Tumor Response 58 tumor necrosis 58 placebo controlled clinical 58 sirolimus eluting stents 58 TAXUS Stent 58 eosinophilia 58 FluCAM arm 58 transcranial Doppler 58 USL# 58 treatment naive genotype 58 venous stasis ulcers 58 factor Xa inhibitor 58 corrected QT interval 58 dabigatran etexilate 58 antitumor effect 58 T2DM 58 MICARDIS 58 EXPAREL TM 58 membranous nephropathy 58 Decitabine 58 Flu Cy 58 APPRAISE 58 intracoronary 58 ribavirin RBV 58 MYCAMINE 58 TAXUS Liberté stent 58 fractional shortening 58 receiving VICTRELIS 58 reteplase 58 plasma kallikrein 58 ORENCIA ® 58 platelet reactivity 58 fenretinide 58 serum urate levels 58 everolimus eluting stents 58 lucinactant 58 tolerability pharmacokinetics 58 balsalazide 58 topically administered 58 NeuroSTAT ® 58 glycopyrrolate 58 microvessel density 58 Kepivance 58 carotid stenosis 58 peritumoral brain edema 58 aerosolized KL4 surfactant 58 CI -#.# 58 p ≤ 58 aldosterone antagonists 58 ENMD # 58 Amphinex ® 58 invasive candidiasis 58 dopaminergic therapy 58 Estradiol 58 Pharmacokinetic studies 58 EBRT 58 AEGR 58 DFMO 58 Elitek 58 LEUKINE 58 paclitaxel eluting stents 58 novel oral anticoagulant 58 arterial thromboembolic events 58 CYT# QbG# 58 Vascugel ® 58 antithrombotic therapy 58 pulmonary arterial 58 TAXUS Express Stent 58 CYT# potent vascular disrupting 58 acromegalic patients 58 angiotensin converting enzyme inhibitors 58 carbidopa levodopa 58 galiximab 58 anti leukemic 58 fluvastatin 58 RLY# 58 ischemic cardiomyopathy 58 TEAEs 58 postintervention 58 severe gastroparesis 58 intradermal injection 58 CYPHER ® 58 Eligen R B# 58 #mg/m# [001] 58 TOVIAZ 58 tocilizumab 58 difluprednate 58 PaO 2 58 mg BID 58 Acute Coronary Syndromes ACS 58 urate lowering therapy 58 dose cohorts 58 lenalidomide dexamethasone 58 Aptivus ® 58 gastrointestinal motility 58 mitral stenosis 58 edoxaban 58 noninferiority 58 PREVENT IV 58 OHR/AVR# 58 interferon alfa 2b 58 Vernakalant 58 endotoxemia 58 bicifadine 58 hour bronchodilation 58 therapeutic regimens 58 alicaforsen enema 58 severe exacerbations 58 pericardial effusion 58 VELCADE melphalan 58 hypertonic saline 58 pegylated interferon alfa 58 tamponade 58 tirofiban 58 lanreotide 58 HGS# 58 cerebrovascular events 58 VIIBRYD 58 Hepatotoxicity 58 gauge vitrectomy 58 direct thrombin inhibitors 58 multikinase inhibitor 58 elagolix 58 Echocardiographic 58 D dimer 58 events AEs 58 Ejection Fraction 58 MIRAPEX 58 prospectively stratified 58 constipation predominant IBS 58 pegylated interferon alfa 2b 58 bupropion SR 58 cTnI 58 ablative therapy 58 See CLINICAL PHARMACOLOGY 58 paclitaxel eluting stent 58 neutrophil count 58 plasma cortisol 58 beta2 agonist 58 tipranavir 58 artery stenosis 58 MAP# 58 pharmacodynamic profile 58 Self Expanding Stent 58 topical formulations 58 rhGH 58 antiplatelet therapies 58 drug eluting stent implantation 58 uricase 58 xenograft models 58 Apoptone 58 ZOLINZA 58 NeuroStar TMS Therapy 58 QT QTc 58 partial agonist 58 HER2 overexpression 58 failure ADHF 58 VP# [004] 58 Platinol ® 58 dose cohort 58 pomalidomide 58 cardiac repolarization 58 radioligand 58 pharmacokinetic parameters 58 relapsing multiple sclerosis 58 CK # administered 58 acetonide FA 58 Bare Metal Stent 58 strontium ranelate 58 sorafenib Nexavar 58 plasminogen activators 58 zolmitriptan 58 urine albumin 58 CG# [003] 58 murine model 58 Catena ® 58 humanized monoclonal 58 Ziprasidone 58 cartilage lesions 58 Adalimumab 58 TMP SMX 58 GORE VIABAHN Endoprosthesis 58 statin monotherapy 58 ischemia reperfusion 58 PrandiMet TM 58 prolonged QT interval 58 imatinib resistant 58 neointimal hyperplasia 58 mapatumumab 58 Darusentan 58 Lubiprostone 58 sargramostim 58 TACE 58 dose escalation phase 58 lactate dehydrogenase LDH 58 Chemophase 58 superficial femoral 58 VIAject ™ 58 corneal ectasia 58 sufentanil 58 mycophenolate mofetil 58 nanomolar 58 opioid analgesia 58 anticholinergic medication 58 liposomal doxorubicin 58 periprocedural 58 malignant neoplasms 58 Acute Decompensated Heart Failure 58 Vidaza azacitidine 58 PRX# 58 atrial tachyarrhythmias 58 brimonidine 58 pharmacodynamic 58 EOquin TM 58 pan HDAC inhibitor 58 recurrent glioblastoma multiforme 58 vasospasm 58 ipratropium bromide 58 unresectable HCC 58 vitreous haze 58 mg QD 58 dose dependently 58 carotid artery stenting 58 cardiac allograft vasculopathy 58 Aloxi injection 58 virologic breakthrough 58 PENNSAID 58 oral candidiasis 58 refractory angina 58 DMARD therapy 58 FDG uptake 58 interferon beta 1b 58 forodesine 58 chemotherapy induced neutropenia 58 IFN γ 58 postoperative AF 58 tigecycline 58 hepatic cirrhosis 58 irbesartan 58 hyperoxia 58 Itraconazole 58 EGFR antibodies 58 dose colchicine 58 Anti Bacterial Envelope 58 AGHD 58 punctal plug drug 58 efalizumab 58 iodixanol 58 EMBEDA ™ 58 ACE Inhibitor 58 menadione 58 Visipaque 58 thromboprophylaxis 58 azelastine 58 pulsatility 58 Double Blind Randomized 58 pharmacodynamic profiles 58 oral corticosteroid 58 vernakalant hydrochloride 58 MADRS score 58 metastatic malignant 58 Perforomist ™ Inhalation Solution 58 RRMS patients 58 INT# [002] 58 REMINYL ® 58 HCD# [002] 58 anastomotic leak 58 knee osteoarthritis OA 58 Fidaxomicin 58 transurethral resection 58 thalidomide Thalomid 58 antimuscarinic 58 oral ibandronate 58 Pharmacodynamic 58 VFEND 58 Diabetic Macular Edema 58 neurologic deficits 58 acne vulgaris 58 vWF 58 BENICAR 58 Epratuzumab 58 darunavir ritonavir 58 tapentadol IR 58 Omacetaxine mepesuccinate 58 Fenretinide 58 EURIDIS 58 intratympanic 58 complement inhibitor eculizumab 58 SPRYCEL ® 58 thyrotropin 58 omega interferon 58 bendamustine 58 Cardiotoxicity 58 alemtuzumab MS 58 dosing cohorts 57 graft patency 57 comparator arm 57 intestinal permeability 57 transaminases 57 oxyhemoglobin 57 Medidur 57 antihypertensive therapy 57 Capecitabine 57 DepoDur TM 57 Liposomal 57 elevated intraocular pressure 57 cerebral perfusion 57 transesophageal 57 LANTUS ® 57 Tolerability 57 intra arterial 57 plus dexamethasone 57 Inosine 57 histone deacetylase HDAC inhibitor 57 intermittent hypoxia 57 + PH# 57 Secondary endpoints include 57 transcranial 57 hemodynamic variables 57 Prospective Randomized 57 cardiac toxicity 57 zonisamide 57 pruritis 57 daunorubicin 57 pramlintide metreleptin combination 57 saline placebo 57 VTE prophylaxis 57 rFSH 57 NOXAFIL 57 HoFH 57 ACE inhibitor ramipril 57 AeroLEF TM 57 hypotensive 57 adjunctive placebo 57 MULTAQ 57 serum phosphate levels 57 cytopenias 57 Fludara 57 GH deficiency 57 either acutely decompensated 57 pamidronate 57 dapsone 57 gemcitabine cisplatin 57 verteporfin 57 schizophrenia CIAS 57 transgene expression 57 BAY #-# 57 opioid bowel dysfunction 57 Biolimus A9 57 VA# [002] 57 AKT inhibitor 57 primary aldosteronism 57 myocardial ischemia 57 rizatriptan 57 concomitant medications 57 ARIXTRA 57 NTx 57 aspartate aminotransferase AST 57 JAK inhibitor 57 creatine kinase MB 57 XL# SAR# 57 intravascular 57 LV ejection fraction 57 r hGH